Amgen ups ShanghaiTech collaboration in research
The US biotechnology company Amgen is working with ShanghaiTech University to further biomedical research through an innovative model.
The company recently announced the start of operation of an Asia Research and Development Center on the campus of ShanghaiTech University. The center will operate with two of the university’s existing biological research institutes, the Shanghai Institute for Advanced Immunochemical Studies and the iHuman Institute.
The R&D model will help create an organic synthesis of industrialization, education and research, said Dr Sean E. Harper, executive vice-president of R&D at Amgen. It will also help improve the ability to scientifically evaluate the efficacy of medicines on Chinese patients, providing them with optimal individualized treatments.
The university’s iHuman Institute and the R&D center have studied G protein-coupled receptors (GPCRs). The research aims to better understand the structure of GPCRs to design more effective medicines.
“Such an innovative model of collaboration between a multinational biotechnology company and domestic research institutes will further enhance our research capabilities in serious diseases and accelerate the development of the biotechnology industry in China,” said Dr Wang Xiaodong, director and investigator of the National Institute of Biological Sciences (Beijing), a member of the National Academy of Sciences and foreign member of the Chinese Academy of Sciences.
China, the world’s second-largest pharmaceutical market, will spend $155 billion to $185 billion on medicines in 2018, according to IMS Health.
Per capita spending on medicines is expected to grow by more than 70 percent in the next five years. Some multinational drugmakers have also stepped up their R&D efforts in China, including Sanofi, Johnson & Johnson and Roche.